JP2017518071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518071A5 JP2017518071A5 JP2017508762A JP2017508762A JP2017518071A5 JP 2017518071 A5 JP2017518071 A5 JP 2017518071A5 JP 2017508762 A JP2017508762 A JP 2017508762A JP 2017508762 A JP2017508762 A JP 2017508762A JP 2017518071 A5 JP2017518071 A5 JP 2017518071A5
- Authority
- JP
- Japan
- Prior art keywords
- chain
- chimeric antigen
- antigen receptor
- seq
- specific multi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 102000009438 IgE Receptors Human genes 0.000 claims 6
- 108010073816 IgE Receptors Proteins 0.000 claims 6
- 210000002865 immune cell Anatomy 0.000 claims 5
- 108020001756 ligand binding domains Proteins 0.000 claims 3
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- -1 ICOS Proteins 0.000 claims 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 108010065816 zeta chain antigen T cell receptor Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987805P | 2014-05-02 | 2014-05-02 | |
| US61/987,805 | 2014-05-02 | ||
| PCT/EP2015/059523 WO2015166056A1 (en) | 2014-05-02 | 2015-04-30 | Cs1 specific multi-chain chimeric antigen receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017518071A JP2017518071A (ja) | 2017-07-06 |
| JP2017518071A5 true JP2017518071A5 (OSRAM) | 2018-06-14 |
Family
ID=53052850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017508762A Pending JP2017518071A (ja) | 2014-05-02 | 2015-04-30 | Ｃｓ１特異的多重鎖キメラ抗原受容体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20170051037A1 (OSRAM) |
| EP (2) | EP3137498A1 (OSRAM) |
| JP (1) | JP2017518071A (OSRAM) |
| AU (1) | AU2015254595B2 (OSRAM) |
| CA (1) | CA2947646A1 (OSRAM) |
| WO (1) | WO2015166056A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2961636A1 (en) | 2014-09-17 | 2016-03-24 | Boris ENGELS | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| KR102558502B1 (ko) * | 2014-12-05 | 2023-07-20 | 시티 오브 호프 | Ｃｓ1 표적화된 키메라 항원 수용체-변형된 ｔ 세포 |
| JP6895890B2 (ja) | 2015-02-10 | 2021-06-30 | ミネルバ バイオテクノロジーズ コーポレーション | ヒト化抗ｍｕｃ１＊ 抗体 |
| IL254817B2 (en) | 2015-04-08 | 2023-12-01 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
| GB201519900D0 (en) * | 2015-11-11 | 2015-12-23 | Ucl Business Plc | Chimeric antigen receptor |
| WO2017192536A1 (en) | 2016-05-02 | 2017-11-09 | University Of Kansas | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy |
| US11951131B2 (en) | 2018-07-03 | 2024-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-SLAMF7 chimeric antigen receptors |
| CN114650829A (zh) * | 2019-09-05 | 2022-06-21 | 索伦托药业有限公司 | 结合bcma的二聚体抗原受体(dar) |
| CN111234033B (zh) * | 2020-01-21 | 2021-05-11 | 南京北恒生物科技有限公司 | 多链嵌合抗原受体及其用途 |
| AU2021294559A1 (en) * | 2020-06-22 | 2023-02-23 | Ramot At Tel-Aviv University Ltd. | Multi subunit protein modules, cells expressing same and uses thereof |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN114907485B (zh) * | 2021-02-08 | 2024-04-26 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| CN116949099B (zh) * | 2023-07-12 | 2024-04-02 | 山东大学第二医院 | 一种靶向cd38和cs1抗原的并联嵌合抗原受体t细胞及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| DK1257632T3 (da) | 2000-02-24 | 2008-01-28 | Xcyte Therapies Inc | Samtidig stimulering og opkoncentrering af celler |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| WO2004083379A2 (en) | 2003-03-14 | 2004-09-30 | Walters Richard E | Large volume ex vivo electroporation method |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| ES2393539T3 (es) * | 2004-03-29 | 2012-12-26 | Abbott Biotherapeutics Corp. | Utilización terapéutica de anticuerpos anti-CS1 |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| CA3133545C (en) | 2012-05-25 | 2023-08-08 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| AU2013312838B2 (en) | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
-
2015
- 2015-04-30 EP EP15720694.7A patent/EP3137498A1/en not_active Withdrawn
- 2015-04-30 WO PCT/EP2015/059523 patent/WO2015166056A1/en not_active Ceased
- 2015-04-30 CA CA2947646A patent/CA2947646A1/en active Pending
- 2015-04-30 JP JP2017508762A patent/JP2017518071A/ja active Pending
- 2015-04-30 AU AU2015254595A patent/AU2015254595B2/en active Active
- 2015-04-30 US US15/308,047 patent/US20170051037A1/en not_active Abandoned
- 2015-04-30 EP EP19159653.5A patent/EP3524616A1/en active Pending
-
2019
- 2019-03-26 US US16/365,367 patent/US20190359680A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518071A5 (OSRAM) | ||
| JP2017519502A5 (OSRAM) | ||
| JP2017522893A5 (OSRAM) | ||
| JP2021087455A5 (OSRAM) | ||
| JP2020114264A5 (OSRAM) | ||
| JP2020511136A5 (OSRAM) | ||
| JP2022113880A5 (OSRAM) | ||
| JP2017524367A5 (OSRAM) | ||
| JP2021094037A5 (OSRAM) | ||
| JP2019527557A5 (OSRAM) | ||
| FI4324851T3 (fi) | BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä | |
| JP2018508219A5 (OSRAM) | ||
| JP2025065142A5 (OSRAM) | ||
| JP2020513754A5 (OSRAM) | ||
| HRP20241057T1 (hr) | Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe | |
| JP2020517295A5 (OSRAM) | ||
| JP2019527537A5 (OSRAM) | ||
| JP2016514462A5 (OSRAM) | ||
| JP2019523301A5 (OSRAM) | ||
| JP2017513478A5 (OSRAM) | ||
| IL277398B2 (en) | Pd-l1 binding affimers, and uses related thereto | |
| JP2020513829A5 (OSRAM) | ||
| JP2017537925A5 (OSRAM) | ||
| IL264144B2 (en) | Antibody 18A2 against CLAUDIN and its use | |
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe |